These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 23673444)
1. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors. Thai HT; Veyrat-Follet C; Mentré F; Comets E Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444 [TBL] [Abstract][Full Text] [Related]
2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA Oncology; 2016; 90(1):10-20. PubMed ID: 26492090 [TBL] [Abstract][Full Text] [Related]
3. Aflibercept: A Review in Metastatic Colorectal Cancer. Syed YY; McKeage K Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191 [TBL] [Abstract][Full Text] [Related]
5. A preclinical and clinical review of aflibercept for the management of cancer. Gaya A; Tse V Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Mitchell EP Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896 [TBL] [Abstract][Full Text] [Related]
11. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962 [TBL] [Abstract][Full Text] [Related]
12. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer. Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346 [No Abstract] [Full Text] [Related]
13. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies. Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738 [TBL] [Abstract][Full Text] [Related]
14. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C; Pherwani N Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964 [TBL] [Abstract][Full Text] [Related]
15. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]. André T; Chibaudel B Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539 [TBL] [Abstract][Full Text] [Related]
16. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
18. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer. Perkins SL; Cole SW Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608 [TBL] [Abstract][Full Text] [Related]
19. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Thai HT; Veyrat-Follet C; Vivier N; Dubruc C; Sanderink G; Mentré F; Comets E Br J Clin Pharmacol; 2011 Sep; 72(3):402-14. PubMed ID: 21575034 [TBL] [Abstract][Full Text] [Related]
20. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]